Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Bcal Diagnostics Ltd

Company price
0.06 AUD -0.00 ( 1.64%)
Last update at 2026-11-13T03:55:00Z
VOLUME
17209
Market Cap
22.12M

Momentum Score

…

BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.06
Low
0.07
High
52 Week Price Range
0.05
Low
0.15
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Bcal Diagnostics Ltd is an Australian-listed company developing and commercialising medical diagnostic tests. Long-term growth may be supported by regulatory approvals, successful clinical validation, commercial partnerships and uptake of its assays, and investors may find exposure to the diagnostics sector and potential intellectual property upside attractive.
Key risks include early-stage product and clinical/regulatory uncertainty, the need for additional funding to progress commercialisation, and competition from established diagnostics firms.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.06
Dividend Yield
-
Revenue TTM
2.35M
Revenue Per Share
0.01
Gross Profit TTM
2.35M
Debt / Equity
-8.37
ROE
-273.29%
Net Debt
5.33M
ROCE
-201.56%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -9.54M -7.24M -9.45M -5.06M -3.39M
Net income -7.37M -7.24M -6.40M -5.06M -3.39M
Selling general administrative - 5.12M 1.64M 3.27M 1.87M
Selling and marketing expenses - 0.27M 0.24M - 0.13M
Gross profit -0.53M 0.02M 3.10M - -
Reconciled depreciation - 1.00M 0.58M 0.11M 0.02M
Ebit -9.39M -7.20M -6.03M -4.73M -3.91M
Ebitda -8.67M -6.19M -5.67M -7.78M -3.89M
Depreciation and amortization 0.72M 1.00M 0.36M - 0.02M
Operating income -9.39M -9.96M -5.45M -5.11M -3.91M
Other operating expenses 9.57M 9.98M 8.55M - 3.91M
Interest expense 0.35M 0.09M 0.10M - 0.00M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.18M 0.05M 0.05M 0.02M
Net interest income - 0.09M -0.05M 0.05M 0.02M
Income tax expense -2.17M -2.63M -3.05M - -0.02M
Total revenue 0.18M 0.02M 3.10M 2.79M 0.72M
Total operating expenses 8.86M 9.98M 8.55M - 3.91M
Cost of revenue 0.72M - 0.58M - -
Total other income expense net -0.15M 2.72M -4.00M 2.79M 0.51M
Net income from continuing ops - -7.24M -6.40M -5.06M -3.39M
Net income applicable to common shares - -7.24M -6.40M -5.06M -3.39M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7.66M 9.91M 12.27M 8.37M 10.59M
Other current assets 0.11M - 0.08M -0.00M 4.00M
Total liab 8.49M 3.69M 3.68M 3.16M 0.95M
Total stockholder equity -0.83M 6.22M 8.59M 5.21M 9.64M
Other current liab 0.59M - 1.13M 0.04M 0.67M
Common stock 34.01M - 28.90M 19.28M 18.87M
Capital stock - 33.83M - 19.28M 18.87M
Retained earnings -35.42M -28.08M -20.98M -14.61M -9.55M
Other liab - - - 0.00M -
Other assets - - 0.00M - -
Cash 1.59M 4.52M 6.47M 3.17M 5.57M
Total current liabilities 3.00M 3.11M 2.60M 2.26M 0.95M
Current deferred revenue - - 0.28M - -
Net debt 5.33M - -4.95M - -5.57M
Short term debt 1.79M - 0.44M 0.00M 0.00M
Short long term debt - 1.58M - - -
Short long term debt total 6.92M - 1.52M - -
Other stockholder equity - - - 0.55M 0.32M
Property plant equipment - - - 2.17M 0.14M
Total current assets 4.07M 7.20M 9.34M 6.20M 10.46M
Net tangible assets - - - 5.21M 9.64M
Short term investments - - - 0.00M 4.00M
Net receivables 2.38M - 2.78M 2.69M 0.01M
Long term debt - 0.12M - - 0.00M
Accounts payable 0.63M 0.55M 0.74M 1.58M 0.28M
Accumulated other comprehensive income 0.59M - 0.67M - 0.32M
Non currrent assets other - - -0.00M - -
Non current assets total 3.59M 2.71M 2.93M 2.17M 0.14M
Capital lease obligations - 0.68M - 1.06M -
Long term debt total - - - 0.90M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.79M -1.15M 4.00M -4.00M
Change to liabilities - - - 0.78M 0.05M
Total cashflows from investing activities -1.44M -0.79M -1.15M 3.64M -4.03M
Net borrowings - 1.08M -0.26M -0.04M -0.04M
Total cash from financing activities 4.66M 4.97M 8.97M 0.01M 9.41M
Net income -7.37M -7.24M -6.40M -5.06M -3.39M
Change in cash -2.94M -1.95M 3.30M -2.40M 2.16M
Begin period cash flow 4.52M 6.47M 3.17M 5.57M 3.41M
End period cash flow 1.59M 4.52M 6.47M 3.17M 5.57M
Total cash from operating activities -6.16M -6.14M -4.52M -6.05M -3.22M
Issuance of capital stock - 4.30M 9.85M 0.05M 10.03M
Depreciation 0.72M - 0.58M 0.11M 0.02M
Other cashflows from investing activities -1.28M - - 4.00M -4.00M
Change to account receivables 0.18M 0.19M 0.16M -2.14M -0.29M
Sale purchase of stock - -0.12M -0.44M 0.05M -0.62M
Other cashflows from financing activities 4.84M -0.29M -0.18M 0.00M -4.03M
Change to netincome - - - 0.27M 0.38M
Capital expenditures 0.46M 0.79M 1.15M 0.36M 4.03M
Change in working capital -0.01M -0.57M 0.61M 1.04M 0.29M
Stock based compensation - - 0.57M - -
Other non cash items 0.50M -5.56M 0.11M - -
Free cash flow -6.62M -6.92M -5.67M -6.05M -4.03M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BDX
Bcal Diagnostics Ltd
-0.00
1.64%
0.06 - - 9.40 10.18 150.40 -1.80
SHL
Sonic Healthcare Ltd
0.09
0.45%
19.98 16.17 17.48 0.90 1.18 1.39 8.24
ACL
Australian Clinical Labs Ltd
-
-%
3.35 27.92 17.45 0.85 4.18 1.29 5.31
IDX
Integral Diagnostics Ltd
-0.01
0.90%
1.65 27.75 15.85 0.79 0.92 1.48 9.23
HLS
Healius Ltd
0.01
0.87%
0.58 - 65.36 0.30 2.44 0.98 10.14

Profile*

Bcal Diagnostics Ltd

BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

50 Clarence Street, Sydney, NSW, Australia, 2000

61 2 9078 7671

Name Title Year Born
Ms. Jayne Andrea Shaw Co-Founder & Exec. Chairman NA
Dr. John G. Hurrell B.Sc, Fulbright Fel, M.Sc(Qual), Ph.D. Chief Exec. Officer NA
Hon. Ronald Anthony Phillips A.O. Co-Founder & Non-Exec. Director NA
Dr. Amani Batarseh Ph.D. Chief Scientist Officer NA
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), C.A., CA, MAICD CFO & Company Sec. 1954
Dr. Jane Ryan Bsc (Hons), M.A.I.C.D., Ph.D. Chief Operating Officer 1959
Sean Kennedy Director of Corp. Fin. NA
Ms. Rebecca Shaw Marketing Mang. NA
Ms. Jayne Andrea Shaw Co-Founder & Executive Chairman NA
Ms. Jayne Andrea Shaw Co-Founder & Executive Chairman NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…